Otros idiomas Vaxxinity, Inc.

Acciones

VAXX

US92244V1044

Biotecnología e investigación médica

Mercado cerrado - OTC Markets Otros sitios de cotización 21:52:29 09/07/2026			Variación 5 días	Varia. 1 de enero.
0,000100 ^USD	-99,15 %		-99,40 %	-66,67 %

20/06/24	Se publican en Nature Medicine los resultados del ensayo UB-312 de Vaxxinity en Parkinson	CI
19/04/24	Vaxxinity se retirará voluntariamente del Nasdaq; las acciones se hunden después de hora	MT

Otros idiomas

20/06/24	Vaxxinity UB-312 Parkinson?s Trial Results Published in Nature Medicine
20/06/24	Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
13/05/24	Vaxxinity, Inc.(OTCPK:VAXX) dropped from S&P Global BMI Index
13/05/24	Vaxxinity, Inc.(OTCPK:VAXX) dropped from S&P TMI Index
08/05/24	Vaxxinity, Inc.(OTCPK:VAXX) dropped from NASDAQ Composite Index
20/04/24	Vaxxinity Issues Shareholder Letter
20/04/24	Vaxxinity Issues Shareholder Letter
19/04/24	Vaxxinity to Voluntarily Delist From Nasdaq; Shares Sink After Hours
19/04/24	Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
28/03/24	Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
27/03/24	Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
27/03/24	Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
27/03/24	Vaxxinity, Inc. Auditor Raises 'Going Concern' Doubt
12/03/24	Vaxxinity : UB-312 Target Engagement - ADPD 2024
07/03/24	Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
07/03/24	Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson?s Disease at AD/PD? 2024
15/02/24	Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
15/02/24	Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies
13/02/24	Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
13/02/24	Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
13/02/24	Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders
30/01/24	Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
30/01/24	Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
30/01/24	Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
18/01/24	Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida